Black checkmark with a sparkle and a curved line underneath on a white background.
Company

TALPHERA, INC.

Ticker
TLPH
Sector
Industry
Report date
November 12, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings call transcripts and highlights for Q1 and Q2 2026, reporting of a $2 million loss in Q1 2026 alongside 50% enrollment completion in the Phase 3 trial, and analyst coverage initiation with a buy recommendation. The company also completed a $29 million private placement in 2025 to support its operations.

Recent developments:
  • Talphera held its Q2 2026 earnings call with detailed discussion of clinical progress and financial results [N1].
  • Q2 2026 earnings call highlights emphasized ongoing Phase 3 trial enrollment and operational updates [N2].
  • The company reported a Q1 2026 loss of $2 million and announced completion of 50% enrollment in its Phase 3 trial [N3].
  • Q1 2026 earnings transcript provided insights into financial performance and clinical development status [N4].
  • WestPark Capital initiated coverage of Talphera with a buy recommendation in May 2026 [N5].
  • Talphera completed 50% enrollment in Phase 3 trial and reported Q3 2024 results and study progress [N6].
  • The company announced a $29 million private placement led by CorMedix and institutional investors in 2025 [N8].
Overview

Talphera, Inc. operates as a clinical-stage biopharmaceutical company engaged in the development and commercialization of pharmaceutical products. Its lead product candidate, Niyad, is undergoing Phase 3 clinical trials with enrollment milestones reported. The company has incurred significant losses since inception and continues to invest heavily in research and development activities. Talphera's financial position as of September 30, 2026, shows cash and short-term investments totaling approximately $14.1 million and a current ratio above 3, indicating liquidity sufficient to meet near-term obligations. However, the company has disclosed substantial doubt about its ability to continue as a going concern without raising additional capital. Talphera's business model depends on successful clinical trial completion, regulatory approvals, and eventual commercialization, with risks including clinical trial delays, regulatory uncertainties, supply chain dependencies, and capital raising challenges. The company maintains effective internal controls and disclosure procedures as per recent SEC filings.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Talphera, Inc. is a clinical-stage biopharmaceutical company focused on pharmaceutical product development, including its lead candidate Niyad in Phase 3 trials. The company reported a net loss of $4.018 million for the nine months ended September 30, 2026, with a strong liquidity position of $10.66 million in cash and $3.5 million in short-term investments as of that date. Talphera has disclosed substantial doubt about its ability to continue as a going concern without additional capital, reflecting ongoing financing needs to support clinical development and commercialization efforts. Recent news includes earnings call transcripts and clinical trial progress updates, alongside a $29 million private placement in 2025. The company faces risks typical of clinical-stage biopharmaceutical firms, including regulatory, operational, and financial uncertainties [S1][S2][N1][N3][N5][N8].

Scenarios for TLPH

Bull case model:

Talphera has advanced its lead product candidate Niyad to Phase 3 clinical trials with significant enrollment progress, demonstrating clinical development momentum. The company has secured financing through a $29 million private placement led by institutional investors, supporting ongoing operations and development activities. Effective internal controls and disclosure procedures have been maintained, and recent analyst coverage includes a buy recommendation. These factors indicate operational execution capability and investor interest in the company's pipeline and potential future commercialization.

Bear case model:

Talphera has disclosed substantial doubt about its ability to continue as a going concern without additional capital, reflecting ongoing financial challenges. The company has incurred significant losses and has not generated meaningful product revenue, with commercialization timelines uncertain. Risks include potential delays or failures in clinical trials, regulatory approval uncertainties, supply chain dependencies on single-source suppliers, and the need to raise additional capital under potentially unfavorable terms. Market volatility and operational risks typical of clinical-stage biopharmaceutical companies also pose challenges to business continuity and growth.

Moat:

Talphera's moat is primarily based on its proprietary pharmaceutical product candidates and ongoing clinical development programs, particularly its lead candidate Niyad in Phase 3 trials. The company's intellectual property, clinical trial data, and regulatory filings contribute to its competitive positioning. However, as a clinical-stage biopharmaceutical company without commercial products generating significant revenue, its moat is contingent on successful product development and regulatory approval. The company faces typical industry risks including competition, regulatory hurdles, and reliance on third-party manufacturers and suppliers.

Risks overview
Risks summary
The most significant risk is the company's substantial doubt about its ability to continue as a going concern without additional capital, which could materially affect its operations and development programs.
Risks details:

• Going Concern and Capital Needs: The company has substantial doubt about its ability to continue as a going concern without raising additional capital, which may impact its ability to fund operations and product development.
• Clinical Trial and Regulatory Risks: Delays or failures in clinical trials or regulatory approvals could increase costs, delay commercialization, or prevent product launch.
• Financial Losses and Profitability: Talphera has incurred significant losses since inception and does not anticipate near-term profitability, relying on external financing to sustain operations.
• Supply Chain Dependencies: Reliance on third-party manufacturers and single-source suppliers for active ingredients may cause delays or increased costs if disruptions occur.
• Market and Operational Risks: The company faces risks from market volatility, competition, regulatory environment changes, and the need to attract and retain qualified personnel.

FINAL FORECAST FOR TLPH

Final take one line
Talphera is a clinical-stage biopharmaceutical company with detailed disclosures on its financial condition, clinical development progress, and capital needs, exhibiting very high visibility into its business model and risks.
Final take 12 to 24 month view

Business trends: Progress in Phase 3 clinical trials with enrollment milestones and ongoing research and development expenditures; continued reliance on external financing to support operations.
Execution milestones: Completion of Phase 3 trial enrollment, maintenance of effective internal controls, and securing capital through private placements.
Key risks: Substantial doubt about going concern status without additional capital, clinical trial and regulatory uncertainties, supply chain dependencies, and ongoing financial losses.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Talphera, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products, including its lead product candidate Niyad.
  • The company has ongoing clinical trials, including a Phase 3 trial for Niyad, with 50% enrollment completed as of Q1 2026.
  • Talphera reported a net loss of $4.018 million for the nine months ended September 30, 2026, with basic EPS of -$0.05 for the same period, indicating ongoing operating losses.
  • As of September 30, 2026, Talphera had cash and cash equivalents of approximately $10.66 million and short-term investments of about $3.5 million, with a current ratio of 3.19 and a cash ratio of 3.06, reflecting a solid liquidity position.
  • The company has disclosed substantial doubt about its ability to continue as a going concern without additional capital, highlighting the need for further financing to support operations and product development.
  • Talphera completed a $29 million private placement led by CorMedix and institutional investors in 2025 to support its operations.
  • The company has incurred significant losses since inception and anticipates continuing losses due to research and development and commercialization expenses.
  • Talphera relies on third-party manufacturers and suppliers for its product candidates, including single sources for active ingredients, which may pose supply chain risks.
  • The company faces risks related to clinical trial delays, regulatory approval uncertainties, and the need to raise additional capital to fund ongoing operations and commercialization efforts.
  • Talphera maintains effective disclosure controls and internal controls over financial reporting as of the latest evaluations.
  • The company has not generated significant product revenue and does not anticipate near-term revenues from product sales in the United States.
  • Talphera's business and financial condition are subject to risks including market volatility, regulatory challenges, and operational execution risks.
  • Recent news includes Q2 2026 earnings call transcripts and highlights, Q1 2026 loss reporting, and updates on clinical trial enrollment progress.
  • WestPark Capital initiated coverage of Talphera with a buy recommendation in May 2026.
  • The company has publicly disclosed its financial figures and risk factors in SEC filings including the 10-K filed March 23, 2026, and 10-Q filed November 12, 2026.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-23 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-08-19 | www.nasdaq.com | Talphera (TLPH) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/talphera-tlph-q2-2026-earnings-call-transcript
  • N2 | 2026-08-13 | www.nasdaq.com | Talphera Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/talphera-q2-earnings-call-highlights
  • N3 | 2026-05-19 | www.nasdaq.com | Talphera Reports Q1 Loss Of $2 Mln; Completes 50% Enrolment In Phase 3 Trial | https://www.nasdaq.com/articles/talphera-reports-q1-loss-2-mln-completes-50-enrolment-phase-3-trial
  • N4 | 2026-05-13 | www.nasdaq.com | Talphera (TLPH) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/talphera-tlph-q1-2026-earnings-transcript
  • N5 | 2026-05-01 | www.nasdaq.com | WestPark Capital Initiates Coverage of Talphera (TLPH) with Buy Recommendation | https://www.nasdaq.com/articles/westpark-capital-initiates-coverage-talphera-tlph-buy-recommendation
  • N6 | 2026-03-24 | www.nasdaq.com | Talphera Reports Q3 2024 Results and Study Progress | https://www.nasdaq.com/articles/talphera-reports-q3-2024-results-and-study-progress
  • N7 | 2025-10-09 | www.nasdaq.com | After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally | https://www.nasdaq.com/articles/after-hours-surge-turn-therapeutics-rockets-134-post-close-nasdaq-debut-biotech-stocks
  • N8 | 2025-09-09 | www.nasdaq.com | Talphera Announces $29 Mln Private Placement Led By CorMedix And Institutional Investors | https://www.nasdaq.com/articles/talphera-announces-29-mln-private-placement-led-cormedix-and-institutional-investors
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine